When Altus reported to CFF that it did not have funds to continue developing the drug, CFF seized control of the asset and eventually licensed it to Alnara Pharmaceuticals, which developed the drug further and was acquired by Eli Lilly in 2010.
When Altus informed CFF of their inability to fund further drug development, CFF took control of the asset and eventually granted a license to Alnara Pharmaceuticals, which advanced the drug and was later purchased by Eli Lilly in 2010.